2024
Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure
Mezzacappa C, Kim N, Vutien P, Kaplan D, Ioannou G, Taddei T. Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure. JAMA Network Open 2024, 7: e2420963. PMID: 38985470, PMCID: PMC11238019, DOI: 10.1001/jamanetworkopen.2024.20963.Peer-Reviewed Original ResearchConceptsHepatitis C virus cureHepatitis C virusAssociated with improved overall survivalHepatocellular carcinoma diagnosisEarly-stage hepatocellular carcinomaImproved overall survivalOverall survivalHepatocellular carcinomaFollow-upHCC screeningCurative treatmentCumulative incidence of hepatocellular carcinomaDirect-acting antiviral (DAA) therapyCohort studyVeterans Affairs health care systemIncidence of hepatocellular carcinomaRisk of hepatocellular carcinomaCohort study of personsHepatitis C virus cirrhosisDiagnosis of hepatocellular carcinomaLikelihood of curative treatmentYears of follow-upHealth care systemHepatocellular carcinoma screeningHCV-related cirrhosis
2020
Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure
Mezzacappa C, Ravindra NG, Caraballo C, Chouairi F, Miller PE, Clarke JD, Gruen J, Mori M, McCullough M, Mullan C, Geirsson A, Rogers JG, Anwer M, Desai N, Ahmad T. Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. PLOS ONE 2020, 15: e0242928. PMID: 33270648, PMCID: PMC7714148, DOI: 10.1371/journal.pone.0242928.Peer-Reviewed Original ResearchConceptsClinical trialsVentricular assist deviceExclusion criteriaLVAD recipientsAssist deviceReal-world settingClinical implicationsClinical trial exclusion criteriaHeart failure clinical trialsEnd-stage renal diseaseEnd-stage heart failureReal-world registryRetrospective cohort studyLandmark clinical trialsStage renal diseaseTrial exclusion criteriaRisk of deathStage heart failureRespiratory failureCohort studyPatient characteristicsHeart failurePatient factorsRenal diseaseClinical outcomesNeurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices
McCullough M, Caraballo C, Ravindra NG, Miller PE, Mezzacappa C, Levin A, Gruen J, Rodwin B, Reinhardt S, van Dijk D, Ali A, Ahmad T, Desai NR. Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices. JAMA Cardiology 2020, 5: 175-182. PMID: 31738366, PMCID: PMC6865330, DOI: 10.1001/jamacardio.2019.4965.Peer-Reviewed Original ResearchConceptsKansas City Cardiomyopathy Questionnaire scoreNeurohormonal blockadeAngiotensin receptor blockersVentricular assist deviceQuality of lifeMineralocorticoid antagonistsReceptor blockersHeart failureWalk testQuestionnaire scoresΒ-blockersEnzyme inhibitorsAssist deviceGuideline-directed medical therapyAngiotensin-converting enzyme inhibitorMechanically Assisted Circulatory SupportHeart failure regimenLeft ventricular assist deviceAdvanced heart failureRetrospective cohort analysisContinuous-flow LVADBetter survival rateOutcomes of interestInteragency RegistryTriple therapy
2019
Clinical Outcomes After Left Ventricular Assist Device Implantation in Older Adults An INTERMACS Analysis
Caraballo C, DeFilippis EM, Nakagawa S, Ravindra NG, Miller PE, Mezzacappa C, McCullough M, Gruen J, Levin A, Reinhardt S, Mullan C, Ali A, Maurer MS, Desai NR, Ahmad T, Topkara VK. Clinical Outcomes After Left Ventricular Assist Device Implantation in Older Adults An INTERMACS Analysis. JACC Heart Failure 2019, 7: 1069-1078. PMID: 31779930, DOI: 10.1016/j.jchf.2019.10.004.Peer-Reviewed Original ResearchConceptsYears of ageVentricular assist device implantationAssist device implantationOlder adultsElderly patientsLVAD implantationDevice implantationMultivariate Cox proportional hazards regression modelCox proportional hazards regression modelKaplan-Meier survival estimatesMechanically Assisted Circulatory SupportProportional hazards regression modelsMechanical circulatory support technologyPost-LVAD outcomesHeart failure populationLog-rank testingSerum albumin levelPredictors of survivalPost-LVAD implantationHazards regression modelsPredictors of outcomeAge-specific outcomesAntithrombotic regimenDurable MCSINTERMACS AnalysisClinical Implications of Respiratory Failure in Patients Receiving Durable Left Ventricular Assist Devices for End-Stage Heart Failure
Miller PE, Caraballo C, Ravindra NG, Mezzacappa C, McCullough M, Gruen J, Levin A, Reinhardt S, Ali A, Desai NR, Ahmad T. Clinical Implications of Respiratory Failure in Patients Receiving Durable Left Ventricular Assist Devices for End-Stage Heart Failure. Circulation Heart Failure 2019, 12: e006369. PMID: 31707800, DOI: 10.1161/circheartfailure.119.006369.Peer-Reviewed Original ResearchMeSH KeywordsAgedDisease ProgressionFemaleFrailtyHealth StatusHeart FailureHeart-Assist DevicesHumansIntubation, IntratrachealLungMaleMiddle AgedProsthesis DesignQuality of LifeRecovery of FunctionRegistriesRespiratory InsufficiencyRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeVentricular Function, LeftConceptsMechanically Assisted Circulatory Support profile 1 patientsVentricular assist device implantationProfile 1 patientsAssist device implantationRespiratory failureInteragency RegistryLVAD implantationCirculatory supportDevice implantationMechanically Assisted Circulatory Support profile 1Right ventricular assist device implantationLeft ventricular assist device implantationAdvanced heart failure patientsEnd-stage heart failureMechanically Assisted Circulatory SupportAdvanced heart failure populationHeart failure populationHeart failure patientsLandmark clinical trialsMechanical circulatory supportContinuous-flow LVADVentricular assist devicePostimplant complicationsFailure patientsLVAD placement